Want to see FR:TNG full AI Analyst Report?
Top Page
Transgene
(TNG)
Select Model
Select Model
Rating:47Neutral
Price Target:
€0.72
▼(-10.38% Downside)
Action:Reiterated
Date:08/20/26
The score is held down primarily by weak financial performance driven by sustained losses, highly volatile/deteriorating revenue, and ongoing cash burn that implies continued reliance on external funding. Technicals are neutral-to-mixed (improving vs. shorter-term averages but still weak vs. the 200-day with only modest momentum). Valuation offers limited support due to negative earnings and no dividend yield data.
Positive Factors
Low Leverage
Very low leverage and a sizable equity base provide Transgene with more financial flexibility than a highly indebted biotech. This reduces direct debt-service pressure and leaves the company better positioned to fund clinical development while managing its ongoing losses.
Negative Factors
Persistent Losses
Persistent losses show that current operations do not yet generate an economically self-supporting business. Deeply negative margins reduce internal funding capacity, increase dependence on successful development outcomes, and make sustained profitability difficult over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage and a sizable equity base provide Transgene with more financial flexibility than a highly indebted biotech. This reduces direct debt-service pressure and leaves the company better positioned to fund clinical development while managing its ongoing losses.
Read all positive factors
Transgene (TNG) vs. iShares MSCI France ETF (EWQ)
Market Cap
€202.59M
Dividend YieldN/A
Average Volume (3M)134.99K
Price to Earnings (P/E)―
Beta (1Y)0.06
Revenue Growth189.81%
EPS Growth38.50%
CountryFR
Employees145
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.17
Shares Outstanding278,559,940
10 Day Avg. Volume102,189
30 Day Avg. Volume134,989
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)1.14
Price to Sales (P/S)282.76
P/FCF Ratio-3.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)€7.63M
Transgene Business Overview & Revenue Model
Company Description
Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and oper...
How the Company Makes Money
Transgene primarily generates revenue through collaboration and partnering arrangements rather than product sales, because it is a clinical-stage company with no widely commercialized products. Key revenue streams typically include: (1) upfront pa...
Transgene Earnings Call Summary
Earnings Call Date:Mar 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Nov 09, 2026
Earnings Call Sentiment Positive
The call emphasized several strong positives: robust fundraising (EUR 105M), a strengthened balance sheet (EUR 39M debt conversion), compelling Phase I efficacy and durable immunogenicity signals for TG4050 (100% disease-free in treated Phase I patients; 73% immunogenicity with responses persisting 24 months), encouraging BT-001 combination data, and a clear plan for manufacturing and regulatory readiness. Counterbalancing these highlights are timing and operational risks (GMP readiness targeted Q3 2027), immature/pending pivotal readouts (Phase II 2-year DFS not yet available), ongoing cash burn (~EUR 38.2M in 2025) and some dependence on broader field validation. Overall, the positive clinical signals and strengthened financial position outweigh the execution and timing risks at this stage.Positive Updates
Successful Fundraising and Balance Sheet Strengthening
Raised approximately EUR 105 million in December 2025 and converted EUR 39 million of debt into equity, leaving the company virtually debt-free and providing financial visibility/runway through early 2028.
Negative Updates
Key Efficacy Readouts Not Yet Mature or Fully Peer-Reviewed
Primary efficacy readout for Phase I/II (2-year DFS for Phase II) is pending until patients reach 2 years post-randomization; Phase I comprehensive analysis is currently a preprint under peer review, so data are not yet fully validated by peer-reviewed publication.
Read all updates
Q4-2025 Updates
Positive
Negative
Successful Fundraising and Balance Sheet Strengthening
Raised approximately EUR 105 million in December 2025 and converted EUR 39 million of debt into equity, leaving the company virtually debt-free and providing financial visibility/runway through early 2028.
Read all positive updates
Company Guidance
The call laid out clear, metric-driven guidance: Transgene raised ~EUR 105m in December 2025 and converted ~EUR 39m of debt to equity (now virtually debt‑free), giving cash visibility through early 2028 (first quarter 2028) after a 2025 cash burn of ~EUR 38.2m; clinically, the primary endpoint for the randomized Phase I/II TG4050 study is 2‑year disease‑free survival (DFS) with an efficacy readout once all patients reach 2 years, Phase I 3‑year DFS data expected Q2–Q3 2026 and 4‑year follow‑up Q2–Q3 2027, Phase II patient randomization to be completed by Q2 2026 and first Phase II immunogenicity data in H2 2026 (with ~1 year follow‑up possible), and Phase I translational results showed 100% DFS at ≥2 years in treated HPV‑negative HNSCC patients vs. 3 relapses in controls and neoantigen‑specific T‑cell responses in 73% of evaluable patients that persisted 24 months; manufacturing and regulatory investments target full GMP capacity by Q3 2027 and a second Phase I indication is slated to start in 2026.Transgene Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
63
Positive
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 313.00K | 490.00K | 6.35M | 7.90M | 3.13M | 9.99M |
| Gross Profit | 13.82M | 490.00K | -27.93M | -21.69M | -29.04M | -22.89M |
| EBITDA | -36.48M | -39.77M | -26.65M | -28.44M | -30.33M | -23.55M |
| Net Income | -33.90M | -37.52M | -33.97M | -22.33M | -32.81M | -20.00M |
Balance Sheet | ||||||
| Total Assets | 124.53M | 138.83M | 42.17M | 45.22M | 66.44M | 101.84M |
| Cash, Cash Equivalents and Short-Term Investments | 92.84M | 111.86M | 16.67M | 15.67M | 26.83M | 49.57M |
| Total Debt | 2.18M | 2.06M | 10.40M | 1.35M | 2.45M | 3.84M |
| Total Liabilities | 15.33M | 17.09M | 26.97M | 29.61M | 28.59M | 34.63M |
| Stockholders Equity | 109.19M | 121.73M | 15.20M | 15.61M | 37.84M | 67.21M |
Cash Flow | ||||||
| Free Cash Flow | -39.29M | -37.58M | -26.62M | -37.42M | -21.84M | -32.63M |
| Operating Cash Flow | -38.09M | -36.74M | -23.55M | -34.67M | -20.30M | -31.94M |
| Investing Cash Flow | -88.22M | -105.95M | -3.21M | 34.57M | 20.27M | 16.79M |
| Financing Cash Flow | 114.06M | 134.38M | 26.96M | 11.37M | -1.48M | 15.77M |
Transgene Technical Analysis
Negative
0.80
Price Trends
0.79
Negative
0.77
Negative
0.80
Negative
Market Momentum
-0.03
Positive
30.51
Neutral
19.31
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:TNG, the sentiment is Negative. The current price of 0.8 is above the 20-day moving average (MA) of 0.80, above the 50-day MA of 0.79, and below the 200-day MA of 0.80, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 30.51 is Neutral, neither overbought nor oversold. The STOCH value of 19.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:TNG.
Transgene Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | €202.59M | -4.23 | -29.36% | ― | 189.81% | 38.50% | |
47 Neutral | €147.67M | -2.57 | 152.56% | ― | -29.48% | 7.91% | |
43 Neutral | €1.14B | -20.31 | 89.71% | ― | ― | ― | |
41 Neutral | €50.82M | -1.26 | -96.73% | ― | -96.25% | -197.89% | |
41 Neutral | €90.26M | -2.10 | -94.14% | ― | -5.98% | -8.67% | |
41 Neutral | €18.67M | -0.51 | ― | ― | -19.02% | 10.39% |
* General Sector Average
FR:TNG
Transgene
0.71
-0.48
-40.34%
FR:IPH
Innate Pharma SA
1.31
-0.47
-26.40%
FR:NANO
Nanobiotix
22.34
0.14
0.63%
FR:OSE
OSE Immunotherapeutics SA
2.14
-4.61
-68.36%
FR:ALCLS
Cellectis SA
1.23
-2.65
-68.35%
FR:MAAT
MaaT Pharma
0.98
-3.53
-78.20%
Transgene Corporate Events
Transgene to Showcase Systemic Oncolytic Virus Data at SITC 2026
Oct 5, 2026
Transgene will present new preclinical data on its enveloped oncolytic virus PoxSTG-EEV, designed for systemic administration, at the Society for Immunotherapy of Cancer annual meeting in Phoenix in early November 2026. The poster, to be unveiled ...
Transgene to Showcase myvac® Cancer Vaccine Platform at Paris Investor Event
Oct 1, 2026
Transgene will present its progress to institutional investors at the Investor Access Event in Paris on October 6, 2026, in a program that brings together more than 190 professional investors and 90 listed companies. Management intends to highligh...
Transgene Advances myvac® Cancer Vaccines and MVA Platform With Cash Runway to 2028
Sep 24, 2026
Transgene reported its 2026 half-year results alongside a broad update on its myvac® oncology platform and MVA-based vaccine pipeline, underscoring progress toward late-stage development and expanded indications. The company highlighted that ...
Transgene Bolsters Viral Vaccine Manufacturing With Expanded ProBioGen Cell-Line Deal
Sep 8, 2026
Transgene and ProBioGen have expanded their collaboration with a new license granting Transgene access to ProBioGen’s AGE1.CR.pIX suspension cell line, a specialized avian platform optimized for viral vaccine production. The technology offer...
Transgene’s TG4050 Vaccine Shows Three‑Year Relapse‑Free Remission in Head and Neck Cancer Trial
Sep 2, 2026
Transgene and NEC reported that all 16 patients treated with TG4050 in the Phase 1 arm of a randomized Phase 1/2 trial for HPV‑negative head and neck cancer remain in clinical remission and relapse‑free after a median follow‑up o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.